Nanotechnology Stocks To Follow Now – February 05th

OSI Systems, NVE, Clene, Virpax Pharmaceuticals, Biodexa Pharmaceuticals, and Clene are the seven Nanotechnology stocks to watch today, according to MarketBeat’s stock screener tool. Nanotechnology stocks refer to shares of companies that are involved in researching, developing, or producing technologies at the nano scale. These companies typically focus on manipulating materials and structures at the molecular or atomic level to create innovative products and solutions with potential applications in various industries such as electronics, healthcare, and energy. Investing in nanotechnology stocks can offer exposure to cutting-edge technologies and potential growth opportunities within the nanotechnology sector. These companies had the highest dollar trading volume of any Nanotechnology stocks within the last several days.

OSI Systems (OSIS)

OSI Systems, Inc. designs and manufactures electronic systems and components. It operates in three segments: Security, Healthcare, and Optoelectronics and Manufacturing. The Security segment offers baggage and parcel inspection, cargo and vehicle inspection, hold baggage and people screening, radiation monitoring, explosive and narcotics trace detection systems, and optical inspection systems under the Rapiscan name.

NASDAQ OSIS traded up $6.08 during mid-day trading on Wednesday, hitting $205.49. The company’s stock had a trading volume of 71,873 shares, compared to its average volume of 219,096. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.88 and a quick ratio of 1.25. OSI Systems has a 52-week low of $126.57 and a 52-week high of $205.34. The stock’s fifty day simple moving average is $176.76 and its two-hundred day simple moving average is $156.65. The firm has a market capitalization of $3.45 billion, a P/E ratio of 26.37, a price-to-earnings-growth ratio of 1.66 and a beta of 1.19.

NVE (NVEC)

NVE Corporation develops and sells devices that use spintronics, a nanotechnology that relies on electron spin to acquire, store, and transmit information in the United States and internationally. The company manufactures spintronic products, including sensors and couplers for use in acquiring and transmitting data.

Shares of NVEC stock traded up $0.81 during mid-day trading on Wednesday, reaching $71.74. The company’s stock had a trading volume of 10,741 shares, compared to its average volume of 28,824. The company’s 50 day simple moving average is $78.34 and its 200-day simple moving average is $79.06. NVE has a 12-month low of $67.35 and a 12-month high of $90.24. The firm has a market capitalization of $347.20 million, a PE ratio of 23.16 and a beta of 1.11.

Clene (CLNN)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

NASDAQ:CLNN traded down $0.13 during mid-day trading on Wednesday, hitting $4.52. The company had a trading volume of 39,656 shares, compared to its average volume of 64,461. Clene has a 1 year low of $3.82 and a 1 year high of $10.65. The business has a fifty day simple moving average of $4.77 and a 200-day simple moving average of $5.05. The firm has a market capitalization of $37.29 million, a price-to-earnings ratio of -0.86 and a beta of 0.24.

Virpax Pharmaceuticals (VRPX)

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.

Shares of NASDAQ:VRPX traded down $0.01 during mid-day trading on Wednesday, hitting $0.28. 224,399 shares of the company traded hands, compared to its average volume of 484,182. Virpax Pharmaceuticals has a 52-week low of $0.23 and a 52-week high of $5.48. The firm’s 50 day simple moving average is $0.35 and its 200 day simple moving average is $0.64.

Biodexa Pharmaceuticals (BDRX)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.

Shares of BDRX traded down $0.11 during mid-day trading on Wednesday, reaching $4.24. 7,658 shares of the stock traded hands, compared to its average volume of 12,731. The firm has a fifty day moving average of $4.47. Biodexa Pharmaceuticals has a 12-month low of $3.50 and a 12-month high of $74.00.

Clene (CLNNW)

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

Clene stock traded up $0.01 during midday trading on Wednesday, hitting $0.04. 15,632 shares of the stock were exchanged, compared to its average volume of 18,667. The company has a 50 day moving average price of $0.04 and a two-hundred day moving average price of $0.04. Clene has a 1 year low of $0.02 and a 1 year high of $0.08.